In a statement released on September 1, 2016 (FDA Black Box Warning), the Food and Drug Administration (FDA) announced that “after an extensive review of the latest scientific evidence, it is requiring class-wide changes to drug labeling, including patient information, to help inform health care providers and patients of the serious risks associated with the […]
The post FDA Mandates New Warnings for Opioid and Benzodiazepines appeared first on The MSP Compliance Blog.
